Charles Homcy joined Third Rock Ventures' in 2010 as a Venture Partner. Charles co-founded Portola Pharmaceuticals in 2003 and served as President and Chief Executive Officer from that time until April 2010.
Prior to that, he was President of Research and Development at Millennium following Millennium's acquisition of COR Therapeutics in 2002. Charles joined COR in 1995 as Executive Vice President of Research and Development, and he served as a Director of the company from 1998 to 2002.
He has been a clinical professor of medicine at the University of California, San Francisco Medical School, and attending physician at the San Francisco VA Hospital since 1997. He was previously President of the medical research division of American Cyanamid-Lederle Laboratories, a division of Wyeth. Charles serves as co-chairman of the board of directors of Portola and is a board member of Geron Corporation. Charles received his AB and MD from Johns Hopkins University.
Interim CEO and Board Member of MyoKardia
Board Member of Cephalon, Inc.
Board Member of CytomX Therapeutics
Board Member and co-founder of Global Blood Therapeutics
Dan Lynch has more than 25 years of experience serving in management positions in the biotechnology and pharmaceutical industries. Since 2007, Dan has advised and served as Executive Chairman or member of the Board of Directors for a number of private biopharmaceutical companies, including Stromedix, Inc. (until its acquisition by Biogen Idec in February 2012) and Avila Therapeutics, Inc. (until its acquisition by Celgene Corporation in February 2012).
Dan is currently Executive Chairman of BIND Therapeutics, Blueprint Medicines, Nimbus Discovery, and RaNa Therapeutics. In addition, Dan is Chairman of bluebird bio and a Director of Ember Therapeutics and is a Venture Partner at Third Rock Ventures.
Previously, Dan served as chief executive and chief financial officer of ImClone Systems Corporation. As ImClone's chief executive officer, he led ImClone through a significant turnaround, helping to restore the company's reputation and to secure FDA approval of ERBITUX (Cetuximab), a novel cancer treatment. As its chief financial officer, Dan led negotiations to form the major partnership between ImClone and Bristol-Myers Squibb. Earlier in his career, he served in various financial positions at Bristol-Myers Squibb over a 15-year tenure. He served on the board of directors and the audit committee of U.S. Oncology, Inc. for five years until December 2010, when it was acquired by McKesson.
Dan received his B.A. in mathematics from Wesleyan University and his M.B.A. from the Darden Graduate School of Business Administration at the University of Virginia.
Board Member of and Chairman of bluebird bio
Board Member and Executive Chairman of Blueprint Medicines
John Maraganore is the Chief Executive Officer of Alnylam Pharmaceuticals. He joined Third Rock in 2013 to participate in a limited capacity focusing on guiding strategy for Third Rock and its portfolio companies.
Prior to joining Alnylam in 2002, John served as an Officer and a member of the management team at Millennium Pharmaceuticals, Inc. As Senior Vice President, Strategic Product Development for Millennium, John was responsible for the company's product franchises in oncology, cardiovascular, inflammation and metabolic diseases. He was previously Vice President, Strategic Planning and M&A, and prior to that, he was General Manager of Millennium BioTherapeutics, Inc., a former subsidiary of Millennium. Before Millennium, he served as Director of Molecular Biology and Director of Market and Business Development at Biogen, Inc. (now Biogen Idec, Inc.). At Biogen, John invented and led the discovery and development of Angiomax™ (bivalirudin for injection, formerly Hirulog™), currently marketed by The Medicines Company. Prior to Biogen, John was a scientist at ZymoGenetics, Inc., and The Upjohn Company. He is Chairman of Regulus Therapeutics and a Director for Tempero Pharmaceuticals.
In addition, he is a member of the Immunology Advisory Council of Harvard Medical School and a member of the Biotechnology Industry Organization board. John received his MS and PhD in biochemistry and molecular biology at the University of Chicago.
Board Member of Agios Pharmaceuticals
Board Member of bluebird bio
Year Joined Third Rock
John Maraganore, PhD
Linda Heath Manager of Operations
and Administration Email
Steve Paul joined Third Rock Ventures in 2010, and serves as a senior advisor to the firm and participates in the ideation and development of potential new companies. Steve has had a distinguished career in neuroscience, particularly in CNS drug discovery and development.
Steve is the former president of the Lilly Research Laboratories of Eli Lilly and Company and now leads the Helen & Robert Appel Institute for Alzheimer's Research at Weill Cornell Medical College. Prior to his appointment at Weill Cornell, Steve spent 17-years at Eli Lilly, during which time he held several key leadership roles, including vice president of neuroscience (CNS) research and group vice president of discovery research (all therapeutic areas). In his most recent role, he was responsible for the company's overall research and development efforts - helping to expand Lilly's R&D efforts in oncology and biotechnology - resulting in a pipeline of approximately 70 new molecular entities. Prior to Lilly, Steve served as Scientific Director of the National Institute of Mental Health. He has also served as Medical Director in the Commissioned Corps of the United States Public Health Service.
Steve has been the recipient of many awards and honors and has served on numerous committees and advisory boards. He has also authored or co-authored over 500 papers and book chapters. Steve is an elected fellow of the American Association for the Advancement of Science and a member of the Institute of Medicine of the National Academy of Sciences. He is also currently on the board of directors or is a trustee of several organizations, including the Sigma-Aldrich Corporation, Alnylam Pharmaceuticals, the Allen Institute for Brain Sciences, The Mind Research Network, and the Foundation for the NIH. Steve has also served as a member of the National Institute of General Medical Sciences (NIGMS) Advisory Council and was appointed by the secretary of the Department of Health and Human Services (HHS) as a member of the advisory committee to the director of the NIH from 2001-2006. Steve is currently a member of the National Advisory Mental Health Council, NIMH, and is board certified by the American Board of Psychiatry and Neurology. Steve has recently been appointed to the Science Board of the FDA.
Steve received his Bachelor of Arts degree in Biology and Psychology from Tulane University in 1972, and his Master of Science and Doctor of Medicine degrees from the Tulane University School of Medicine in 1975.
Phillip Reilly joined Third Rock Ventures in 2009 and supports the firm’s founding and advancement of new ventures, with a particular focus on seeking to nurture and grow transformational companies dedicated to breakthrough treatments for genetic disorders.
Phil is an accomplished entrepreneur and has a long-standing interest in genetic testing and in developing new therapies for genetic diseases. Phil is currently a trustee of Cornell University and is on the Board of Overseers of Weill Cornell Medical College. He served twice as president of the American Society of Law, Medicine and Ethics. He is a founding fellow of the American College of Medical Genetics, and the the author of several books about clinical genetics. Phil has held teaching positions at Tufts University School of Medicine and Harvard Medical School, and serves on the scientific advisory board member of bluebird bio and is a board observer at Edimer Pharmaceuticals.
Phil holds an M.D. from Yale University, a J.D. from Columbia University, is a member of the Massachusetts Bar and is board certified in internal medicine and clinical genetics.
Scientific Advisory Board Member of bluebird bio, former interim CMO
Greg Verdine joined Third Rock Ventures in 2009, and provides scientific due diligence for the firm's potential portfolio investments. Greg is a thought leader in the field of chemical biology and an accomplished drug discovery entrepreneur.
Greg has served as the Erving Professor of Chemistry in the Harvard University Departments of Stem Cell and Regenerative Biology, Chemistry and Chemical Biology, and Molecular and Cellular Biology for the past 25 years. He discovered the molecular mechanism of epigenetic DNA methylation and elucidated the pathway by which certain genotoxic forms of DNA damage are eradicated from the genome. Greg is also responsible for having developed a new class of therapeutics termed stapled peptides, which are currently in clinical development and have received much attention for their ability to drug “undruggable” targets.
Greg has co-founded multiple biotechnology companies, including Enanta Pharmaceuticals, Gloucester Pharmaceuticals, Aileron Therapeutics, Tokai Pharmaceuticals, Ontorii Pharmaceuticals and Eleven Biotherapeutics. For more than a decade, he served as one of two global consultants for Hoffmann-La Roche, and was a founding scientific advisor to Vertex Pharmaceuticals, Ariad Pharmaceuticals and Variagenics, Inc.
Greg serves as a scientific advisor to the board of directors of the Ibusuki Medipolis Research Institute; on the board of scientific consultants of the Memorial Sloan-Kettering Research Institute; on the board of scientific advisors of the National Cancer Institute; and the scientific advisory board of the SMA Foundation.
Greg holds a Ph.D. in chemistry from Columbia University, a B.S. in chemistry from St. Joseph’s University, and served as an NIH postdoctoral fellow in molecular biology at MIT and Harvard Medical School.